SecBot SecBot
PRESS-RELEASE ·Filed Jun 16, 2026

IVVD

Invivyd
NEUTRAL
Impact 5/10
Horizonweeks Processed5mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight • Neutral

Monitor Q3 2026 for LIBERTY and DECLARATION topline data; positive safety/tolerability comparison could support BLA filing and differentiate VYD2311 from vaccines. Stock may trade on binary data readout risk.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$0.8918
T+0 close · Jun 16, 2026 · via day close
Latest settled
−13.00%
T+60 · $0.7759
Vs SPY
−14.00%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 16 $0.8918entry
  2. T+1 · 5mo ago +4.42%α +5.67% · $0.9312
  3. T+5 · 5mo ago +4.80%α +7.03% · $0.9346
  4. T+20 · 4mo ago −10.20%α −10.40% · $0.8008
  5. T+60 · 2mo ago −13.00%α −14.00% · $0.7759
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Invivyd announced completion of enrollment in its Phase 3 LIBERTY trial comparing VYD2311 (monoclonal antibody) against an mRNA COVID vaccine, with topline data expected in Q3 2026. The trial is part of the broader REVOLUTION program aiming to position VYD2311 as an alternative to vaccines. This is a clinical milestone with no efficacy or safety data yet, so the immediate stock impact is limited.

Key Facts

  • Phase 3 LIBERTY trial enrollment complete; ~210 participants randomized, double-blind.
  • Primary endpoint: safety/tolerability of VYD2311 vs mRNA COVID vaccine through Day 6.
  • Topline data expected in Q3 2026, potentially alongside DECLARATION pivotal trial data.
  • VYD2311 is engineered from same backbone as pemivibart (EUA for immunocompromised PrEP) and adintrevimab.
  • DECLARATION trial (n~2,400) is placebo-controlled evaluating VYD2311 efficacy in preventing symptomatic COVID.
  • No efficacy or safety data released yet; forward-looking statements only.

Financial Impact

No financial data disclosed; clinical milestone with no revenue or cost figures.

Risk Factors

  • LIBERTY or DECLARATION may fail to show superiority or non-inferiority vs vaccine/placebo.
  • Regulatory pathway uncertain; FDA may require additional trials for BLA.
  • Viral evolution could reduce VYD2311 neutralizing activity.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
89% bullish (9 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3312427

Track record

19 reports on IVVD

Performance horizon

3 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +35.85% at T+20 after the Jul 6, 2026 report. 4 of 5 went positive at some point.

Filters
  1. Nov 16, 2026today Press Release Neutral 6/10 Entry $0.5603 Now $0.5380 −3.98% settles Nov 23
  2. Nov 3, 202613d ago Press Release Neutral 2/10 Entry $0.5815 to $0.5744 Now $0.5380 −7.48% ▼ −1.22% −0.63% vs SPY
  3. Sep 29, 20266w ago 8-K Bullish 7/10 Entry $0.8501 to $0.8064 Now $0.5380 −36.71% ▼ −5.14% −7.09% vs SPY
  4. Sep 22, 20267w ago Institutional Cluster Mixed 3/10 Entry $0.9640 to $0.8501 Now $0.5380 −44.19% ▼ −11.82% −10.63% vs SPY
  5. Sep 1, 202610w ago 8-K Neutral 6/10 Entry $0.8800 to $0.7973 Now $0.5380 −38.86% ▼ −9.40% −9.48% vs SPY
  6. Aug 17, 202613w ago 144 Neutral 2/10 Entry $0.8680 to $0.9387 Now $0.5380 −38.02% ▲ +8.15% +8.35% vs SPY
  7. Jul 6, 202619w ago 8-K Bearish 6/10 Entry $0.8340 to $0.7834 Now $0.5380 +35.49% ▲ +6.07% +6.56% vs SPY
  8. Jun 16, 202621w ago Press Release Neutral 5/10 Viewing Entry $0.8918 to $0.9346 Now $0.5380 −39.67% ▲ +4.80% +7.03% vs SPY
  9. Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $0.8125 to $0.9312 Now $0.5380 −33.78% ▲ +14.61% +14.18% vs SPY
  10. Jun 9, 202622w ago Press Release Neutral 4/10 Entry $0.9900 to $0.8686 Now $0.5380 −45.66% ▼ −12.26% −14.67% vs SPY
Showing 10 of 19

US Market Status

Market Closed · Opens in 6h 15m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 16, 2026